merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Safety and FDA approval</answer>

<question_number>2</question_number>
<answer>By offering direct-to-door delivery of FDA-approved medication at competitive prices through its own telehealth platform</answer>

<question_number>3</question_number>
<answer>Lack of FDA oversight and safety concerns</answer>

<question_number>4</question_number>
<answer>To recapture customers who have turned to cheaper compounded alternatives</answer>

<question_number>5</question_number>
<answer>Compounding pharmacies can legally make copycat versions of medications on the FDA shortage list, but once tirzepatide is removed from this list, "there should be no space for mass compounders"</answer>

<question_number>6</question_number>
<answer>Offering "transparent pricing" by "removing third-party supply chain entities"</answer>

<question_number>7</question_number>
<answer>Older Medicare patients might purchase the cheaper vials despite potential health risks specific to their age group</answer>

<question_number>8</question_number>
<answer>Positioning its vials as a safer FDA-approved alternative to compounded drugs that lack safety, quality and effectiveness controls</answer>

<question_number>9</question_number>
<answer>Being listed as "in shortage" by the FDA</answer>

<question_number>10</question_number>
<answer>Lower pricing</answer>